A new report revealing that drug discounts are not being passed on to consumers has sparked political outrage, highlighting a system where Swiss patients struggle to access innovative medicines.
"This is organised theft. The law is clear: discounts on medicine prices must go back to insurers and policyholders."
"Pharmaceutical companies are already delaying or foregoing the launch of new therapies in Switzerland to avoid jeopardising their prices in the US."
A staggering CHF 655 million intended for Swiss patients is being siphoned off by the very institutions meant to provide care. While the pharmaceutical industry grants nearly CHF 743 million in annual discounts, a bombshell report from the Federal Audit Office (SFAO) reveals that only 12% of that valueâa measly CHF 88 millionâactually reaches the pockets of insured citizens. This systemic failure has ignited a firestorm in Bern, with Socialist Party MP Baptiste Hurni branding the practice as 'organised theft.' Under Swiss law, these savings must be passed on to health insurers and policyholders, yet hospitals, doctors, and pharmacists are accused of utilizing 'inventive accounting' to retain the lion's share. This financial leakage occurs while Swiss households grapple with relentless increases in health insurance premiums, creating a bitter contrast between institutional profit and public burden. The Federal Office of Public Health (FOPH) now faces intense scrutiny for its failure to oversee a supply chain that has become a black hole for consumer savings.
Swiss patients are being denied access to a staggering one-third of all newly developed, innovative medicines. Despite Switzerland's reputation as a global pharmaceutical hub, a new Interpharma report warns that the nation is suffering a 'serious threat' to equal access. In a direct comparison, Switzerland currently offers only half of the new therapies available to patients in Germany. Between January 2025 and June 2026, pharmaceutical giants opted not to submit seven out of 22 innovative medicines for inclusion on the list of specialties. For three other critical treatments, companies didn't even bother filing for authorization with Swissmedic. This isn't just a bureaucratic delay; it is a calculated retreat that leaves patients with life-altering conditionsâfrom rare genetic mutations to aggressive cancersâwaiting for treatments that may never arrive on Swiss soil. The decline in patient care is no longer a hypothetical risk; it is a present reality.
The 'most-favoured-nation' (MFN) clause in US drug policy is casting a long, dark shadow over Swiss hospitals. To protect their lucrative American profit margins, pharmaceutical companies are strategically withholding new drug launches in Switzerland. Because US regulations often tie domestic prices to international benchmarks, a lower price in Switzerland could trigger a mandatory price collapse in the United States. Consequently, Swiss patients have become collateral damage in a global pricing war. Interpharma notes that 10 new treatments were intentionally withheld from the Swiss market for the 2025â2026 period to avoid jeopardizing US revenue. This geopolitical chess game means that even the wealthiest nation in Europe cannot guarantee its citizens the latest medical breakthroughs. The Swiss pricing system is now fundamentally incompatible with international trends, forcing a choice between high costs or no access at all.
Developing a single new drug now costs a staggering $2.23 billion, a 65% surge over the last decade. This astronomical figure, highlighted by Deloitte, reflects the move away from simple chemical pills toward complex biologics and gene therapies. These modern 'miracle' drugs, such as monoclonal antibodies for cancer or mRNA-based vaccines, require unprecedented levels of laboratory precision and quality control. While these innovations offer hope for previously untreatable diseases, they come with scientific and economic challenges that are pushing the industry to its breaking point. In Switzerland, the focus on 'specialty drugs' for small patient populations means that the cost per patient is soaring. As research timelines lengthen and laboratory costs skyrocket, the tension between the pharmaceutical industry's need for ROI and the public's right to affordable care has reached a critical breaking point.
The era of opacity in the Swiss pharmaceutical supply chain is coming to an end as parliamentarians demand immediate reform. Thomas BlĂ€si, a Geneva MP and pharmacist, insists that the Federal Office of Public Health can no longer plead ignorance while insurance premiums soar. The 'inventive accounting' models used to hide discounts are being compared to criminal enterprises, and the political pressure for a complete system overhaul is reaching a fever pitch. When Parliament reconvenes in September, the SFAO report will serve as an indictment of the current status quo. Switzerland stands at a crossroads: it must either implement a transparent pricing system compatible with global realities or watch its world-class healthcare system erode from within. For the Swiss public, the message is clearâthe days of paying premium prices for second-tier access must end. The fight for the 'stolen' CHF 655 million is just the beginning.